Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRIS-IPF: Bexotegrast in Idiopathic Pulmonary Fibrosis
NCT04396756Phase 2Completed
- Sponsor
- Pliant Therapeutics
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of bexotegrast in idiopathic pulmonary fibrosis (IPF), sponsored by Pliant Therapeutics. Started Mar 2020; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04396756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396756.